Levodopa Benefits Neovascular Age-Related Macular Degeneration
TUESDAY, Sept. 15, 2020 -- Levodopa is a safe and well-tolerated treatment for neovascular age-related macular degeneration (nAMD) and improves visual outcomes, according to a study recently published in The American Journal of Medicine. Anna G.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 15, 2020 Category: Pharmaceuticals Source Type: news

Levodopa may improve vision in patients with macular degeneration
(Elsevier) Investigators have determined that treating patients with an advanced form of age-related macular degeneration (AMD) with levodopa, a safe and readily available drug commonly used to treat Parkinson's disease, stabilized and improved their vision. It reduced the number of treatments necessary to maintain vision, and as such, will potentially reduce the burden of treating the disease, financially and otherwise. Their findings appear in The American Journal of Medicine, published by Elsevier. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 10, 2020 Category: International Medicine & Public Health Source Type: news

RegenxBio is growing — and pushing its eye disease treatment through yet another clinical trial
The Rockville biotech is trying to change the game for patients with wet age-related macular degeneration and diabetic retinopathy. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 27, 2020 Category: Biotechnology Authors: Sara Gilgore Source Type: news

Artificial intelligence recognizes deteriorating photoreceptors
(University of Bonn) A software based on artificial intelligence (AI), which was developed by researchers at the Eye Clinic of the University Hospital Bonn, Stanford University and University of Utah, enables the precise assessment of the progression of geographic atrophy (GA), a disease of the light sensitive retina caused by age-related macular degeneration (AMD). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 13, 2020 Category: International Medicine & Public Health Source Type: news

Phase III data show Roche ’s Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration
Basel, 22 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from the phase III Archway study evaluating its investigational Port Delivery System with ranibizumab (PDS) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD), a leading cause of blindness globally.1 In Archway, 98.4% of PDS patients were able to go six months without needing additional treatment and achieved vision outcomes equivalent to patients receiving monthly ranibizumab eye injections, a current standard of care. In the study, PDS was generally well-tolerated, with a favourable benefit...
Source: Roche Media News - July 22, 2020 Category: Pharmaceuticals Source Type: news

Phase III data show Roche ’s Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration
Basel, 22 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from the phase III Archway study evaluating its investigational Port Delivery System with ranibizumab (PDS) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD), a leading cause of blindness globally.1 In Archway, 98.4% of PDS patients were able to go six months without needing additional treatment and achieved vision outcomes equivalent to patients receiving monthly ranibizumab eye injections, a current standard of care. In the study, PDS was generally well-tolerated, with a favourable benefit...
Source: Roche Investor Update - July 22, 2020 Category: Pharmaceuticals Source Type: news

Scientists identify a new drug target for dry age-related macular degeneration
(Sanford Burnham Prebys Medical Discovery Institute) Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that the blood protein vitronectin is a promising drug target for dry age-related macular degeneration (AMD), a leading cause of vision loss in Americans 60 years of age and older. The study, published in the Proceedings of the National Academy of Sciences (PNAS), also holds implications for Alzheimer's and heart disease, which are linked to vitronectin. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - July 20, 2020 Category: International Medicine & Public Health Source Type: news

Interim Six-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosa
Click to Access Audio Press ReleaseRARITAN, NJ, July 17, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today six-month data from the ongoing Phase 1/2 trial (NCT03252847) of its investigational gene therapy for the treatment of inherited retinal disease X-linked retinitis pigmentosa (XLRP). The interim data showed that low and intermediate doses of the investigational adeno-associated virus retinitis pigmentosa GTPase regulator (AAV-RPGR) were generally well-tolerated and indicated significant improvement in vision. Initial data on the novel AAV-RPGR asset, jointly developed with Meir...
Source: Johnson and Johnson - July 17, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Combating drug resistance in age-related macular degeneration
(Baylor College of Medicine) An international team of researchers led by Baylor College of Medicine and Houston Methodist has discovered a strategy that can potentially address a major challenge to the current treatment for age-related macular degeneration, (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 16, 2020 Category: International Medicine & Public Health Source Type: news

Artificial Intelligence Passes Macular Degeneration Test Artificial Intelligence Passes Macular Degeneration Test
A deep-learning system accurately diagnosed age-related macular degeneration in a real-life population in a prospective clinical trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 29, 2020 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Nanoscope received NIH support for its first-in-class delivery approach to restore vision
(Nanoscope Technologies) Researchers at Nanoscope ® Technologies, LLC are advancing development of therapeutic gene and delivery platform for treating degenerative eye diseases such as dry age-related macular degeneration (dry-AMD) which affects a significant portion of the global population. Nanoscope was just awarded a multi-million dollar grant from National Eye Institute, a division of the NIH, for advancing the spatially-targeted non-viral spatially-targeted gene delivery platform and Multi-Characteristic Opsin for AMD therapy. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - May 28, 2020 Category: International Medicine & Public Health Source Type: news

AI Systems Predict the Course of Macular Degeneration AI Systems Predict the Course of Macular Degeneration
Two new artificial intelligence algorithms can predict the development of age-related macular degeneration, researchers say.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 27, 2020 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

AI Model Predicts Risk for Age-Related Macular Degeneration
WEDNESDAY, May 27, 2020 -- A new artificial intelligence algorithm can predict risk for age-related macular degeneration (AMD), according to a study published in the April issue of Translational Vision Science and Technology. Alauddin Bhuiyan,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 27, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration
Basel, 27 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the phase III Archway study, evaluating Port Delivery System with ranibizumab (PDS) in people living with neovascular or “wet” age-related macular degeneration (nAMD). PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customised formulation of ranibizumab over a period of months. The Archway trial met its primary endpoint, demonstrating that patient s with PDS who received refills every six months achieved visual acuity outcomes equivalent to tho...
Source: Roche Investor Update - May 27, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration
Basel, 27 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the phase III Archway study, evaluating Port Delivery System with ranibizumab (PDS) in people living with neovascular or “wet” age-related macular degeneration (nAMD). PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customised formulation of ranibizumab over a period of months. The Archway trial met its primary endpoint, demonstrating that patient s with PDS who received refills every six months achieved visual acuity outcomes equivalent to tho...
Source: Roche Media News - May 27, 2020 Category: Pharmaceuticals Source Type: news

Study finds unexpected suspect in age-related macular degeneration
(eLife) Scientists have identified an unexpected player in the immune reaction gone awry that causes vision loss in patients with age-related macular degeneration (AMD), according to a new study published today in eLife. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 5, 2020 Category: Biology Source Type: news

I am an eye surgeon but could soon be your doctor in the ICU. I'm terrified
I am fearful for the future, uncertain for how my skills will hold up when put to testCoronavirus – latest updatesSee all our coronavirus coverageI am an ophthalmologist. I am the doctor you see for your cataract surgery, the doctor your grandmother sees to have her age-related macular degeneration checked, the one who prescribed the bedtime drops to slow down your grandfather ’s glaucoma. In the next few weeks I will be the doctor your father sees for his stroke, the doctor who treats your grandmother’s heart failure, the doctor you see in A&E to treat your asthma. Potentially the doctor you meet in ...
Source: Guardian Unlimited Science - April 20, 2020 Category: Science Authors: Selina Khan Tags: Coronavirus outbreak Doctors Society Health Society Professionals Infectious diseases Science NHS Work & careers Guardian Careers Source Type: news

UC Riverside biochemist spins out joint venture company with Atomwise
(University of California - Riverside) Over the past few years, biochemist John Jefferson Perry at the University of California, Riverside, has collaborated on a number of projects with Atomwise Inc., a company that uses artificial intelligence for drug discovery. Now Perry and the company have formed a joint venture called Theia Biosciences. It will focus initially on helping treat age-related macular degeneration through developing small molecule inhibitors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 13, 2020 Category: International Medicine & Public Health Source Type: news

NIH researchers discover tooth-enamel protein in eyes with dry AMD
(NIH/National Eye Institute) A protein that normally deposits mineralized calcium in tooth enamel may also be responsible for calcium deposits in the back of the eye in people with dry age-related macular degeneration (AMD), according to a study from researchers at the National Eye Institute (NEI). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 13, 2020 Category: International Medicine & Public Health Source Type: news

Wireless Photovoltaic Device Restores Central Visual Sensitivity in Atrophic Age-Related Macular Degeneration Wireless Photovoltaic Device Restores Central Visual Sensitivity in Atrophic Age-Related Macular Degeneration
A wireless photovoltaic device implanted subretinally can restore central visual sensitivity in patients with geographic atrophy, an advanced form of age-related macular degeneration (AMD), according to a first-in-human clinical trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 9, 2020 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Novartis stands by safety of eye drug amid ongoing review
Swiss drugmaker Novartis said on Monday the safety data available for its eye drug Beovu to treat wet age-related macular degeneration (wet AMD) continued to support its use as it conducts a review into the safety of the drug. (Source: Reuters: Health)
Source: Reuters: Health - March 2, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

European Medicines Agency Grants PRIME and Advanced Therapy Medicinal Product Designations to Janssen ’s RPGR Gene Therapy for X-Linked Retinitis Pigmentosa
RARITAN, NJ, March 2, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Medicines Agency (EMA) has granted both PRIME (PRIority MEdicines) and Advanced Therapy Medicinal Product (ATMP) designations to the company’s adeno-associated virus (AAV)-RPGR gene therapy product for the treatment of inherited retinal disease X-linked retinitis pigmentosa (XLRP). PRIME is awarded to increase interactions, optimize development plans and accelerate innovative treatments where there is unmet medical need. Similarly, ATMP status is granted to medicines that are based on gen...
Source: Johnson and Johnson - March 2, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

New discovery has important implications for treating common eye disease
(Trinity College Dublin) Scientists from Trinity College Dublin have made an important discovery with implications for those living with a common, debilitating eye disease (age-related macular degeneration, AMD) that can cause blindness. They have discovered that the molecule TLR2, which recognises chemical patterns associated with infection in the body, also seems to play an important role in the development of retinal degeneration. When TLR2 is removed in model systems, a degree of protection is conferred. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 20, 2020 Category: Biology Source Type: news

Not All With AMD May Need Continuing Treatment Not All With AMD May Need Continuing Treatment
A small number of patients with neovascular age-related macular degeneration (nAMD) continue to maintain good vision years after cessation of anti-VEGF therapy, according to an analysis of trial results.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 11, 2020 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Protein in blood may signal age-related macular degeneration, researchers say
An international team of researchers has identified a new protein that could provide a platform for improved diagnosis and treatment of age-related macular degeneration, or AMD. (Source: Health News - UPI.com)
Source: Health News - UPI.com - February 7, 2020 Category: Consumer Health News Source Type: news

With Macular Degeneration, 1 Missed Visit to Eye Doc Can Mean Vision Loss
FRIDAY, Feb. 7, 2020 -- Missing just one eye doctor appointment can result in vision loss in older adults with macular degeneration, a new study warns. Age-related macular degeneration (AMD) is a leading cause of vision loss in the elderly, and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 7, 2020 Category: General Medicine Source Type: news

International team delivers research breakthrough for leading cause of blindness
(Queen Mary University of London) Researchers have identified a new protein linked to age-related macular degeneration (AMD) that could offer new hope for the diagnosis and treatment of the disease, which affects over 1.5 million people in the UK alone. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 7, 2020 Category: International Medicine & Public Health Source Type: news

Visit Adherence, Visual Acuity Linked in Macular Degeneration
THURSDAY, Feb. 6, 2020 -- Adherence to randomized clinical trial visits is associated with visual acuity in individuals with neovascular age-related macular degeneration, according to a study published online Feb. 6 in JAMA Ophthalmology. Meera S.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 6, 2020 Category: Pharmaceuticals Source Type: news

Drug Trials Snapshots: BEOVU
BEOVU is a treatment for neovascular (wet) Age-Related Macular Degeneration (AMD). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 27, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Potential way to halt blinding macular degeneration identified
(University of Virginia Health System) It would be the first treatment for dry age-related macular degeneration and could significantly improve treatment for wet AMD. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 22, 2020 Category: International Medicine & Public Health Source Type: news

Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular Degeneration (AMD) and Diabetic Macular Edema
The program, facilitated by Johnson & Johnson Innovation, has the potential to improve the treatment of patients with retinal vascular diseases and transform the lives of those suffering from vision loss. CAMBRIDGE, England, Jan. 13, 2020 -- (Healthcare... Biopharmaceuticals, Ophthalmology Exonate, Janssen Pharmaceuticals, Johnson & Johnson, macular degeneration (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 13, 2020 Category: Pharmaceuticals Source Type: news

Poor Diet Linked to Age-Related Macular Degeneration
Study offers more reasons to limit processed foods, fatty meats and dairy ... You are leaving AARP.org and going to the website of our trusted provider. ... The provider ’s terms, conditions and pol... (Source: AARP.org News)
Source: AARP.org News - January 6, 2020 Category: American Health Source Type: news

Fatty Diets Tied to Vision Loss in Seniors
A study has linked diets high in red meat and fatty foods to age-related macular degeneration in seniors. (Source: WebMD Health)
Source: WebMD Health - December 26, 2019 Category: Consumer Health News Source Type: news

NIH launches first U.S. clinical trial of patient-derived stem cell therapy to replace dying cells in retina
NEI-led study to test safety of treatment for a form of age-related macular degeneration that currently lacks treatment. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - December 16, 2019 Category: American Health Source Type: news

Western Diet Linked to Late Age-Related Macular Degeneration
FRIDAY, Dec. 13, 2019 -- Consumption of a Western dietary pattern is associated with an increased likelihood of developing late age-related macular degeneration (AMD), according to a study published online Dec. 6 in the British Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 13, 2019 Category: Pharmaceuticals Source Type: news

Study finds association between poor diet, age-related macular degeneration
(University at Buffalo) Participants who ate a diet high in red and processed meat, fried food, refined grains and high-fat dairy were three times more likely to develop late-stage age-related macular degeneration. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2019 Category: International Medicine & Public Health Source Type: news

Kodiak Sciences Announces Sale of Future Royalties on KSI-301 for $225 Million to Baker Bros. Advisors
Kodiak Sells Capped Royalty Right on Global Net Sales of KSI-301 for $225 million Royalty Rate of 4.5% on Annual Net Sales Terminates after 4.5 times the Funded Amount Has Been Paid Transaction Enables an Immediate Acceleration of Clinical, Manufactu... Biopharmaceuticals, Ophthalmology, Venture Capital Kodiak Sciences, age-related macular degeneration (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 2, 2019 Category: Pharmaceuticals Source Type: news

Rates of leading cause of blindness will almost DOUBLE in Europe by 2025
Researchers from Bonn University in Germany said ageing populations meant 15 per cent more people across Europe would suffer from age-related macular degeneration in 30 years' time. (Source: the Mail online | Health)
Source: the Mail online | Health - November 12, 2019 Category: Consumer Health News Source Type: news

Yale researchers find cells linked to leading cause of blindness in elderly
Scientists have pinpointed the glial cells and vasculature cells responsible for age-related macular degeneration. (Source: Yale Science and Health News)
Source: Yale Science and Health News - October 24, 2019 Category: Universities & Medical Training Source Type: news

Novartis blockbuster eye med wins FDA approval
Beovu injections treat wet age-related macular degeneration that affects 20 million people worldwide, according to the company (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 8, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves New Injection Brolucizumab (Beovu ) for Wet AMD FDA Approves New Injection Brolucizumab (Beovu ) for Wet AMD
The US Food and Drug Administration approved brolucizumab (Beovu, Novartis) injection for wet age-related macular degeneration (AMD).FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - October 8, 2019 Category: Drugs & Pharmacology Tags: Ophthalmology News Alert Source Type: news

FDA Approves Beovu (brolucizumab-dbll) for the Treatment of Wet Age-Related Macular Degeneration (AMD)
EAST HANOVER, N.J., Oct. 8, 2019 /PRNewswire/ -- Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Beovu (brolucizumab-dbll) injection, also known as RTH258, for the treatment of wet age-related macular degeneration... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 8, 2019 Category: Drugs & Pharmacology Source Type: news

Reticular Pseudodrusen a Risk for More Rapid AMD Progression Reticular Pseudodrusen a Risk for More Rapid AMD Progression
Patients with reticular pseudodrusen (RPD)-associated age-related macular degeneration (AMD) are at increased risk of progression to geographic atrophy, researchers sayReuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 23, 2019 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Yet Another Health Problem Linked to Air Pollution: Eye Disease
It’s no secret that air pollution isn’t good for your health. In particular, exposure to the byproducts of burning the fuel that powers most of our motor vehicles has been linked to higher risk of lung cancer, respiratory infections, stroke and heart disease, as well as an increased risk of death from these conditions. A new study now adds another worrisome pollution-related risk: eye disease. Dr. Suh-Hang Hank Juo, from the center for myopia and eye disease at China Medical University in Taiwan, and his colleagues documented for the first time in a large population that exposure to two common air pollutants&md...
Source: TIME: Health - August 22, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized health macular degeneration Pollution Source Type: news

High Levels of Exhaust Pollutants May Raise Risk for AMD High Levels of Exhaust Pollutants May Raise Risk for AMD
Exposure to high levels of exhaust may raise the risk of age-related macular degeneration (AMD), a new study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 22, 2019 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Exposure to Air Pollutants May Up Risk for Macular Degeneration
WEDNESDAY, Aug. 21, 2019 -- Chronic exposure to high levels of nitrogen dioxide (NO2) and carbon monoxide (CO) is associated with an increased risk for age-related macular degeneration (AMD) in a population in Taiwan, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 21, 2019 Category: Pharmaceuticals Source Type: news

High levels of exhaust pollutants may raise risk for degenerative eye disease
(Reuters Health) - Exposure to high levels of exhaust may raise the risk of the vision robbing disease called age-related macular degeneration (AMD), a new study suggests. (Source: Reuters: Health)
Source: Reuters: Health - August 21, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Star Trek-style visor helps five blind patients see again
The volunteers, who all had age-related macular degeneration, had taken part in a trial of the French tech firm Pixium Vision's 'bionic' system. (Source: the Mail online | Health)
Source: the Mail online | Health - July 26, 2019 Category: Consumer Health News Source Type: news

New Age-Related Macular Degeneration Common in Untreated Fellow Eyes New Age-Related Macular Degeneration Common in Untreated Fellow Eyes
New age-related macular degeneration (AMD) develops in about a quarter of fellow eyes to those treated for neovascular AMD with intravitreal anti-VEGF agents, according to a post hoc analysis of the VIEW 1 and VIEW 2 studies.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 18, 2019 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Tips for boosting eye health and avoiding macular degeneration
(Natural News) Age-related macular degeneration (AMD) is a disease that can lead to vision loss. It affects over 10 million adults in the U.S. alone, and this number is expected to double by the year 2050. While there is no cure for macular degeneration, certain steps can be taken to boost eye health and decrease the risk of... (Source: NaturalNews.com)
Source: NaturalNews.com - July 15, 2019 Category: Consumer Health News Source Type: news